胆管がん - 世界の臨床試験のレビュー（2024年）

当レポートでは、胆管がんの臨床試験について調査分析し、各国の臨床試験数と平均登録数のデータや、主要企業のレビューと関連する臨床試験のリストなどを提供しています。

目次

表のリスト

図表のリスト

• レポートガイダンス
• GlobalDataの臨床試験レポートのカバー範囲
• 臨床試験：地域別
• 臨床試験と平均登録数：国別
• アジア太平洋の臨床試験に寄与している上位5ヶ国
• 欧州の臨床試験に寄与している上位5ヶ国
• 北米の臨床試験に寄与している上位国
• 中東・アフリカの臨床試験に寄与している上位5ヶ国
• 中南米の臨床試験に寄与している上位5ヶ国
• G7諸国による臨床試験：腫瘍の臨床試験に占める胆管がんの割合
• G7諸国の臨床試験：フェーズ別
• G7諸国の臨床試験：試験ステータス別
• E7諸国による臨床試験：腫瘍の臨床試験に占める胆管がんの割合
• E7諸国の臨床試験：フェーズ別
• E7諸国の臨床試験：試験ステータス別
• 臨床試験：フェーズ別
• 進行中の試験：フェーズ別
• 臨床試験：試験ステータス別
• 臨床試験：エンドポイントステータス別
• 一定期間にわたって採用された被験者
• 臨床試験：スポンサータイプ別
• 著名なスポンサー
• 胆管がん治療の臨床試験に参加している主要企業
• 著名な薬物
• 胆管がんに関する最新の臨床試験ニュース
• 2024年11月5日：胆道がん患者がMAST試験で2年以上完全寛解を維持
• 臨床試験プロファイルのスナップショット
• 略語
• 定義
• 調査手法
• 二次調査
• GlobalDataについて
• お問い合わせ
• 免責事項
• 情報源

List of Tables

• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Region, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, North America, Top Countries, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2024*
• Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, G7 Countries (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024*
• Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, E7 Countries (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Phase, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024*

List of Figures

• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Region (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2024*
• Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, G7 Countries (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024*
• Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, E7 Countries (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Phase (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024*
• Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024*
• GlobalData Methodology

GlobalData's clinical trial report, "Bile Duct Cancer (Cholangiocarcinoma) - Global Clinical Trials Review, 2024" provides an overview of Bile Duct Cancer (Cholangiocarcinoma) Clinical trials scenario. This report provides top line data relating to the clinical trials on Bile Duct Cancer (Cholangiocarcinoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level
• Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

List of Tables

List of Figures

• Report Guidance
• GlobalData Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Five Countries Contributing to Clinical Trials in Middle East and Africa
• Top Five Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials
• Prominent Drugs
• Latest Clinical Trials News on Bile Duct Cancer (Cholangiocarcinoma)
• Nov 05, 2024: Bile Tract Cancer Patient maintains Complete Response in MAST Study for Over Two Years
• Clinical Trial Profile Snapshots
• Abbreviations
• Definitions
• Research Methodology
• Secondary Research
• About GlobalData
• Contact Us
• Disclaimer
• Source